Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients
Metrics: PDF 1889 views | HTML 2146 views | ?
Shushan Yan1,*, Guangwang Dang2,*, Xiaoyu Zhang3,*, Chengwen Jin4, Lang Qin5, Yugang Wang6, Min Shi6, Haijin Huang7 and Quanhong Duan1
1Department of Gastrointestinal and Anal Diseases Surgery, The Affiliated Hospital of Weifang Medical University, Weifang, China
2Department of Outpatient, People’s Hospital of Zoucheng, Zoucheng, China
3Division of Gastrointestinal Surgery, Department of General Surgery, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, China
4Functional Laboratory, Clinical Medicine College of Weifang Medical University, Weifang, China
5Department of Image, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
6Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7Department of General Surgery, Hongze District People's Hospital, Hongze, China
*These authors have contributed equally to this work
Quanhong Duan, email: [email protected]
Haijin Huang, email: [email protected]
Keywords: colon cancer, exosomes, microRNA-638, prognosis
Received: May 13, 2017 Accepted: June 19, 2017 Published: July 29, 2017
Exosome-encapsulated microRNAs have been recognized as novel and stable biomarkers for cancer. However, little is known about the role of exosomal microRNAs in colon cancer. In the present study, we investigated the expression of serous exosomal microRNA-638 (miR-638) and its prognostic effect in patients with colon cancer. Serous exosomal samples were assayed by quantitative real-time PCR. Kaplan-Meier analysis was adopted to determine the overall survival (OS) and disease-free survival (DFS) of colon cancer patients. Cox regression analysis was applied to assess the potential association between serous exosomal miR-638 and clinicopathological factors of colon cancer patients. MiR-638 was significantly reduced in serum exosomes of colon cancer patients compared with healthy controls. Decreased level of serous exosomal miR-638 was more significant in colon cancer patients at later TNM stage or with liver metastasis. Kaplan-Meier analysis showed that colon cancer patients with reduced level of serous exosomal miR-638 had poor OS and DFS. In addition, the Cox regression analysis suggested serous exosomal miR-638 was a prognostic factor for colon cancer independent of TNM stage and liver metastasis. In conclusion, serous exosomal miR-638 is a useful biomarker for the prediction of colon cancer prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.